Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Karina Yoon Ph.D.
Associate Professor
Close
E-mail
kyoon@uab.edu
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Karina Yoon Ph.D.
Associate Professor
Positions
Scientist
,
Cancer Cell Biology
,
O'Neal Comprehensive Cancer Center
Associate Professor (P)
,
Pharmacology and Toxicology
,
Academic Joint Departments
2009 -
Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
2009 -
Associate Scientist (C)
,
Comprehensive Neuroscience Center
,
General Clinical Research Center
2014 -
Publications
Research
Teaching
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2020
Developing effective combination therapy for pancreatic cancer: An overview
.
Pharmacological Research
. 155.
2020
2020
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
.
Cancer Letters
. 468:48-58.
2020
2019
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
.
EBioMedicine
. 44:419-430.
2019
2018
FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer
.
Cancer Letters
. 436:75-86.
2018
2018
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma
.
Oncotarget
. 9:22665-22679.
2018
2018
Pediatric anaplastic embryonal rhabdomyosarcoma: Targeted therapy guided by genetic analysis and a patient-derived xenograft study
.
Frontiers in Oncology
. 7.
2018
2018
JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma
.
Molecular Cancer Therapeutics
. 17:107-118.
2018
2017
Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors
.
Scientific Reports
. 7.
2017
2016
The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype
.
Cancer Research
. 76:3978-3988.
2016
2016
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
.
Oncogene
. 35:833-845.
2016
2016
Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin
.
Oncotarget
. 7:86660-86674.
2016
2015
ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin
.
Oncogene
. 34:1553-1562.
2015
2015
The role of ICAM-2 in neuroblastoma
.
Oncoscience
. 2:915-916.
2015
2013
Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma
.
PLoS ONE
. 8.
2013
2013
N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells
.
BMC Cancer
. 13.
2013
2009
Cell adhesion molecules as targets for therapy of neuroblastoma.
.
Cancer Biology and Therapy
. 8:306-311.
2009
2008
ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma
.
PLoS ONE
. 3.
2008
2007
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma
.
Cancer Research
. 67:22-25.
2007
2006
Development of a tumor-selective approach to treat metastatic cancer
.
PLoS ONE
. 1.
2006
2006
Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy.
.
Molecular Cancer Therapeutics
. 5:1577-1584.
2006
2005
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
.
Chemico-Biological Interactions
. 157-158:247-252.
2005
2005
Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety.
.
Journal of Medicinal Chemistry
. 48:5543-5550.
2005
2005
The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
.
Molecular Pharmacology
. 67:1874-1881.
2005
2005
Development of prodrugs for enzyme-mediated, tumor-selective therapy.
2005
2004
Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
.
Molecular Cancer Therapeutics
. 3:903-909.
2004
2003
Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
.
Molecular Cancer Therapeutics
. 2:1171-1181.
2003
2003
Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism
.
Bioorganic and Medicinal Chemistry
. 11:3237-3244.
2003
Research
Principal Investigator On
Developing Novel Combination Therapies for Pancreatic Cancer
awarded by
National Cancer Institute/NIH/DHHS
2016 - 2021
Developing Therapy for the Treatment of Cholangiocarcinoma
awarded by
National Cancer Institute/NIH/DHHS
2016 - 2019
Investigator On
Role of PIM Kinase in Maintaining Hepatoblastoma Tumor Initiating Cell Population
awarded by
KAUL PEDIATRIC RESEARCH INSTITUTE
2017 - 2019
Glycan Control of Stem Cell-Associated Pathways in Pancreatic Cancer
awarded by
National Cancer Institute/NIH/DHHS
2015 - 2017
Teaching
Teaching Activities
missing activity
2020
missing activity
2020
missing activity
2020
missing activity
2020
missing activity
2019
missing activity
2019
missing activity
2019
missing activity
2019
missing activity
2018
missing activity
2018
missing activity
2018
missing activity
2017
missing activity
2016
missing activity
2016
missing activity
2016
missing activity
2015
missing activity
2014
missing activity
2011
Background
Education And Training
Doctor of Philosophy in Pharmacology,
Florida Agricultural & Mechanical University
2001
Contact
Full Name
Karina
Yoon